Biomarkers of Dietary Omega-6 Fatty Acids and Incident Cardiovascular Disease and Mortality

Abstract

Background: Global dietary recommendations for and cardiovascular effects of linoleic acid, the major dietary omega-6 fatty acid, and its major metabolite, arachidonic acid, remain controversial. To address this uncertainty and inform international recommendations, we evaluated how in vivo circulating and tissue levels of linoleic acid (LA) and arachidonic acid (AA) relate to incident cardiovascular disease (CVD) across multiple international studies. Methods: We performed harmonized, de novo, individual-level analyses in a global consortium of 30 prospective observational studies from 13 countries. Multivariable-adjusted associations of circulating and adipose tissue LA and AA biomarkers with incident total CVD and subtypes (coronary heart disease (CHD), ischemic stroke, cardiovascular mortality) were investigated according to a prespecified analytical plan. Levels of LA and AA, measured as % of total fatty acids, were evaluated linearly according to their interquintile range (i.e., the range between the mid-point of the first and fifth quintiles), and categorically by quintiles. Study-specific results were pooled using inverse-variance weighted meta-analysis. Heterogeneity was explored by age, sex, race, diabetes, statin use, aspirin use, omega-3 levels, and fatty acid desaturase 1 genotype (when available). Results: In 30 prospective studies with medians of follow-up ranging 2.5 to 31.9 years, 15,198 incident cardiovascular events occurred among 68,659 participants. Higher levels of LA were significantly associated with lower risks of total CVD, cardiovascular mortality, and ischemic stroke, with hazard ratios per interquintile range of 0.93 (95% CI: 0.88-0.99), 0.78 (0.70-0.85), and 0.88 (0.79-0.98), respectively, and nonsignificantly with lower CHD risk (0.94; 0.88-1.00). Relationships were similar for LA evaluated across quintiles. AA levels were not associated with higher risk of cardiovascular outcomes; comparing extreme quintiles, higher levels were associated with lower risk of total CVD (0.92; 0.86-0.99). No consistent heterogeneity by population subgroups was identified in the observed relationships. Conclusions: In pooled global analyses, higher in vivo circulating and tissue levels of LA and possibly AA were associated with lower risk of major cardiovascular events. These results support a favorable role for LA in CVD prevention. What is new?• We conducted the hitherto largest pooled individual-level analysis using circulating and adipose tissue levels of linoleic acid and arachidonic acid to examine the link between omega-6 fatty acids and cardiovascular outcomes in various populations.• Our approach increases statistical power and generalizability compared to individual studies; lowers the risk of publication bias and heterogeneity compared to metaanalyses of existing literature; and allows evaluation of the associations in key population subgroups.• Strikingly, higher level of linoleic acid was associated with lower risks of total cardiovascular disease, ischemic stroke, and cardiovascular mortal...

Genome-Wide Association Study for Serum Omega-3 and Omega-6 Polyunsaturated Fatty Acids: Exploratory Analysis of the Sex-Specific Effects and Dietary Modulation in Mediterranean Subjects with Metabolic Syndrome

“…In general, it is accepted that plasma fatty acids reflect a short term fatty acid intake whereas erythrocyte levels reflect a more long term intake. This limitation is also present in the studies meta-analyzing populations with different fatty acid determinations and may have an influence when comparing results [130]. Moreover, an additional limitation, even in studies analyzing plasma fatty acids, is the type of measurement.…”

“…However, to better understand dietary modulation, a gene*diet interaction analysis should be carried out. Although some GWAS and various candidate gene studies have examined the interaction between several dietary components (food or nutrients) and the genetic variants in determining PUFA concentrations [1,60,83,[129][130][131][132][133][134][135], the interaction with a whole dietary pattern such as the Mediterranean diet pattern [99], has not been comprehensively investigated. In an exploratory study, taking into account our limited sample size, we explored gene* Mediterranean diet interactions at the genome-wide level in determining serum PUFA.…”

Plasma Phospholipid Fatty Acids, FADS1 and Risk of 15 Cardiovascular Diseases: A Mendelian Randomisation Study

“…Observational studies of the association between individual FAs and ischemic stroke, including large-artery stroke, are relatively limited and the findings are conflicting, possibly because of small sample sizes of some studies and residual confounding. Most but not all studies support that moderate or high ALA [28] and LA [29,30] and low SA [31,32] exposure is associated with lower risk…”

Exploring the causal pathway from omega-6 levels to coronary heart disease: A network Mendelian randomization study

“…Omega-6 fats are polyunsaturated fats vital for many physiological functions [20], but their effect on CHD risk is debated. Most real-world studies tend to support a protective role for omega-6 fats in CHD [6,22]. Yet there have been different findings recently.…”